In-depth healthcare analysis and news for business executives.
Ninety percent of Americans support patient access to unapproved treatments for terminal illnesses, a new Goldwater Institute survey finds, with bipartisan majorities backing FDA modernization for personalized medicine.
1d ago
R Street Institute analysis argues DEA's proposed Schedule I ban on 7-OH would block research and push users to illegal markets, recommending product regulation over prohibition instead.
2d ago
Small biotech firms controlling 70 percent of clinical-stage drugs face existential threat from Most-Favored-Nation pricing model as investment plummets and White House expands enforcement.
3d ago
Massachusetts universities and hospitals generated $130 billion in output and supported 705,000 jobs, but federal NIH cuts threaten the state's research-driven economy and could displace 300,000 from health coverage.
4d ago
NIH cut 67% of early-career training grants by 2026, prompting a Milken Institute report urging philanthropy to fund postdoctoral researchers and early-career scientists to preserve US biomedical leadership.
5d ago
Obamacare premiums will rise 14% in 2027, driven by arbitration disputes that reached 2.5 million cases and cost overruns, highlighting structural flaws requiring reform.
6d ago
Blood tests can now detect Alzheimer's using a simple draw, but a Milken Institute report finds health systems lack readiness to adopt these FDA-cleared biomarkers widely.
Jul 12, 2026
Maryland's new law allows pharmacists to prescribe buprenorphine for opioid addiction, expanding access through over 1,000 pharmacies after 969 opioid deaths this year, reducing treatment barriers.
Jul 11, 2026
States are spending millions from $52 billion in opioid settlements on drug-disposal programs despite prescription opioids no longer driving overdose deaths, while proven interventions remain underfunded.
Jul 10, 2026
